Chong Kun Dang presents CKD-DAC data and analysts rate Chong Kun Dang stock

Published on 10/20/2026 at 01:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Seven analysts set a KRW 102,857 target in a three-month survey. Chong Kun Dang stock posted Q2 revenue of KRW 478.47 billion, up 10.00 percent.

Clinical data and earnings context

At an October 16, 2026 presentation, Chong Kun Dang disclosed preclinical CKD-DAC results.
Second-quarter 2026 revenue rose 10.00 percent year on year to KRW 478.47 billion.
Chong Kun Dang's market capitalization was KRW 892.0 billion as of October 19, 2026.

Chong Kun Dang, KR7185750007, Illustration mit AI erstellt.

Chong Kun Dang presented preclinical results for its CKD-DAC antibody-drug conjugate platform on October 16, 2026, giving the pharmaceutical company a fresh research catalyst. ATS View reported that the company disclosed the data at the World ADC event in San Diego, with coverage focusing on the platform's potential to address resistance in existing antibody-drug conjugate treatments.

CKD-DAC adds a research catalyst

The October 16, 2026 disclosures form the latest company-specific event in the available coverage. ATS View listed three related reports and described the work as a clinical and approvals catalyst, while Chong Kun Dang remains a pharmaceutical group focused on manufacturing, distribution, research and development.

The research story follows an October 8, 2026 ownership disclosure involving Chong Kun Dang Holdings and a 40.15 percent holding in the pharmaceutical company, according to the ownership information summarized by ATS View. That filing added a governance angle to the stock's recent news flow.

What does earnings growth mean for margins?

Chong Kun Dang's second-quarter 2026 revenue reached KRW 478.47 billion, up 10.00 percent from KRW 435.00 billion in the second quarter of 2025. Operating profit moved the other way, falling to KRW 18.62 billion from KRW 23.60 billion, a decline of 21.10 percent. Net income increased to KRW 20.00 billion from KRW 19.40 billion, or 3.07 percent. The figures are reported in the quarterly series compiled from DART filings by ATS View.

The next test is the third quarter. MoneyToday reported on October 11, 2026 that analysts expected revenue of KRW 485.70 billion, up 13.00 percent year on year, while operating profit estimates ranged from KRW 19.10 billion to KRW 23.00 billion. The spread highlights the margin question created by imported products and lower-margin sales.

Valuation remains below the yearly high

Seven analysts in a three-month consensus survey put the average 12-month target at KRW 102,857, with estimates ranging from KRW 80,000 to KRW 130,000, according to Investing.com. Chong Kun Dang's market capitalization stood at KRW 892.0 billion on October 19, 2026, while its 52-week range was KRW 63,000.00 to KRW 98,100.00. The combination of research progress and uneven operating profit leaves clinical execution and margin delivery as the central investor questions.